HALLANDALE BEACH, Fla.–(BUSINESS WIRE)–ClorNasal™: A revolutionary intranasal therapy system named 2021 & 2022 Finalist by the worldwide Congress on Pharmacological Ingredients (CPhI) in two categories of a prestigious award in the international pharmaceutical industry. ClorNasal™ was a finalist for finished formulation in 2021 and 2022 as well as a finalist for innovation in COVID-19 response for 2021 out of the hundreds of international applicants. Dr. Ferrer BioPharma is proud of this major accomplishment.
The team at Dr. Ferrer BioPharma is known for being the leading innovators in intranasal medications for the treatment of cough, colds, flu, and allergies. Through their advanced technologies, they created high-quality, evidence-based, consumer-focused products, invented by doctors in the service of improving patient outcomes. The focus of Dr. Ferrer BioPharma is to help people Breathe Better™.
ClorNasal™ was selected as a finalist for solving a myriad of problems commonly encountered by other treatments of allergic rhinitis, Influenza, RSV and COVID-19 including:
- VIRAL INFECTIONS – This formula contains a broad-spectrum antiviral medication that treats upper respiratory tract infections (a known side effect of nasal corticosteroids).
- PATIENT DISCOMFORT – ClorNasal™ includes the revolutionary GentleMist Technology™ nozzle, now being sold worldwide, developed by Dr. Ferrer BioPharma to minimize the burn and pain associated with intranasal therapies.
- POOR DRUG DISTRIBUTION IN THE NASAL CAVITY– GentleMist Technology™, is also optimized for even particle distribution (no dripping), and improved drug target delivery.
- INCORRECT APPLICATION AND ADMINISTRATION – Dr. Ferrer BioPharma’s scientists in collaboration with fluid dynamics engineers have researched and determined the correct positioning to apply a nasal spray for optimal effective target delivery.
Dr. Ferrer BioPharma is continuing research on the use of ClorNasal™ as a cutting-edge treatment to prevent and treat COVID-19, Influenza, and RSV for adult and pediatric populations. ClorNasal™ is currently available in various Latin American countries. Dr. Ferrer BioPharma is following the regulatory steps to bring ClorNasal™ to the United States, Canada, and Europe.
About Dr. Ferrer BioPharma
We are the leading innovators in intranasal medications for the treatment of cough, colds, flu, and allergies. We use advanced technology to bring high-quality, evidence-based, consumer-focused, and doctor-invented products to the market. DrFerrerBioPharma.com
A special thanks to Broward County, FL for awarding Dr. Ferrer BioPharma an Enterprise Florida Grant by the Office of Economic Development, to participate at CPhI Worldwide 2022.
Contacts
Maria Jacobo
VP of Communications
954.918.4880
MJ@Dr.FerrerBioPharma.com